Epivir-HBV: A Comprehensive Overview of Its Use in Hepatitis B Management > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Epivir-HBV, known generically as lamivudine, is an oral antiviral medication specifically indicated for the treatment of chronic hepatitis B virus (HBV) infection. It belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class of drugs, which function by inhibiting the reverse transcriptase enzyme essential for viral replication. By incorporating itself into the growing viral DNA chain, lamivudine causes premature chain termination, thereby suppressing the replication of HBV and reducing the viral load in the patient's bloodstream.

Pharmacology and Mechanism of Action
Lamivudine is a synthetic nucleoside analogue of cytidine. After cellular uptake, it is phosphorylated to its active form, lamivudine triphosphate. This active metabolite competes with the natural substrate, deoxycytidine triphosphate, for incorporation into viral DNA by the HBV polymerase (reverse transcriptase). Once incorporated, it halts DNA chain elongation. This inhibition is selective for viral polymerases, though it also exhibits activity against human immunodeficiency virus (HIV), a critical consideration in co-infected patients. The standard dosage for chronic hepatitis B in adults is 100 mg once daily, which is distinct from the higher 150 mg or 300 mg doses used for HIV treatment. This differentiation is crucial to prevent the emergence of HIV resistance in undiagnosed co-infected individuals.

Clinical Efficacy and Indications
Epivir-HBV is indicated for the treatment of chronic hepatitis B in adults and children (aged 2 years and above) with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels, and histological evidence of active liver inflammation and/or fibrosis. Clinical trials have demonstrated its effectiveness in achieving several key therapeutic endpoints:
Virological Response: A significant reduction in serum HBV DNA levels, often to undetectable limits by standardized assays.
Serological Response: Promotion of hepatitis B e antigen (HBeAg) seroconversion (loss of HBeAg and development of anti-HBe antibodies), which is associated with improved long-term outcomes.
Biochemical Response: Normalization of serum ALT levels.
Histological Improvement: Reduction in liver necroinflammation and fibrosis scores in follow-up liver biopsies.

The drug has proven particularly valuable in managing patients with advanced liver disease, including compensated cirrhosis, and is used in transplant settings to prevent HBV recurrence.

Resistance and Limitations
A major limitation of lamivudine monotherapy is the high rate of antiviral resistance with prolonged use. Resistance is primarily mediated by mutations in the YMDD motif of the HBV polymerase gene, most commonly the rtM204V/I mutation. The incidence of genotypic resistance increases with treatment duration, approximating 15-30% after one year and up to 70% after five years of therapy. The emergence of resistance can lead to virological breakthrough (reappearance of HBV DNA), biochemical breakthrough (re-elevation of ALT), and potential progression of liver disease. This high resistance profile has led to lamivudine being largely superseded by newer, more potent agents with higher genetic barriers to resistance (e.g., entecavir, tenofovir) as first-line monotherapy in many treatment guidelines.

Safety and Adverse Effects
Epivir-HBV is generally well-tolerated. The most common adverse reactions reported in clinical trials include headache, fatigue, dizziness, nausea, diarrhea, and upper respiratory infections. These are typically mild to moderate in severity. Several serious safety considerations exist:
Lactic Acidosis and Severe Hepatomegaly: A rare but serious syndrome characterized by lactic acidosis and pronounced liver enlargement has been reported with nucleoside analogues, necessitating caution in patients with risk factors for liver disease.
Exacerbations of Hepatitis B: Severe acute exacerbations of hepatitis B have been observed upon discontinuation of therapy. Patients must be closely monitored for several months after stopping Epivir-HBV, and treatment may need to be reinitiated.
Pancreatitis: Cases of pancreatitis have been reported, particularly in pediatric patients; use in children requires careful monitoring.
HIV Co-infection: The 100 mg dose must not be used for HIV treatment. Unrecognized or untreated HIV-1 co-infection can lead to HIV resistance.

Role in Current Treatment Paradigms
While newer antivirals are preferred for initial treatment due to superior resistance profiles, lamivudine retains a role in specific clinical scenarios. It may be considered in short-term prophylaxis (e.g., during chemotherapy to prevent HBV reactivation), in certain resource-limited settings due to its lower cost and wide availability, or in combination therapy regimens. Its established safety profile in pregnancy (Pregnancy Category C) also makes it an option in certain cases of maternal HBV, though tenofovir is often preferred. Furthermore, it serves as a component of some fixed-dose combination therapies.

Conclusion
Epivir-HBV (lamivudine) represents a foundational agent in the historical and ongoing management of chronic hepatitis B. Its introduction marked a significant advance, offering effective viral suppression and histological benefit. However, Benzac AC Gel: Tratamiento Eficaz para el Acné (lhospitalvet.es) its utility as long-term monotherapy is constrained by a high rate of resistance development. In contemporary practice, its use is often guided by specific clinical circumstances, duration considerations, and local guidelines, with a preference for newer, high-barrier-to-resistance nucleos(t)ide analogues for first-line chronic management. As with all antiviral therapies for hepatitis B, treatment with Epivir-HBV requires careful patient selection, diligent monitoring for efficacy and adverse events, and awareness of the risks associated with treatment cessation.